FDA to assess 'female Viagra'

Boehringer Ingelheim's drug aimed at increasing women's sexual desire is being questioned by Food and Drug Administration (FDA) staff, who said it "failed to demonstrate a statistically significant improvement."

Boehringer Ingelheim's drug aimed at increasing women's sexual desire is being questioned by Food and Drug Administration (FDA) staff, which said it “failed to demonstrate a statistically significant improvement."

The drug, if approved, would be the first in the market to treat low libido in premenopausal women, creating what could be a $2 billion market on par with men's drugs like Viagra, Levitra, and Cialis, says The New York Times.

The Times adds that the company is already promoting the issue of women's low libido through the use of a website, Twitter, documentary, and spokesperson and actress Lisa Rinna. The drug, called flibanserin, will be presented to the FDA's Reproductive Health Drugs Advisory Committee on June 18.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.